• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Greenwich LifeSciences Inc.

    11/3/25 5:09:59 PM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLSI alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    Greenwich LifeSciences, Inc.
    (Name of Registrant as Specified in its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required
       
    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      (1) Title of each class of securities to which transaction applies:
         
      (2) Aggregate number of securities to which transaction applies:
         
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
         
      (4) Proposed maximum aggregate value of transaction:
         
      (5) Total fee paid:
         

     

    ☐ Fee paid previously with preliminary materials:
       
    ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

      (1) Amount Previously Paid:
         
      (2) Form, Schedule or Registration Statement No.:
         
      (3) Filing Party:
         
      (4) Date Filed:
         

     

     

     

     
     

     

     

     
     

     

     

     
     

     

     

     
     

     

     

     

     

     

    Get the next $GLSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLSI

    DatePrice TargetRatingAnalyst
    8/20/2025$45.00Outperform
    Noble Capital Markets
    9/1/2021$78.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $GLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $38,502 worth of shares (4,600 units at $8.37), increasing direct ownership by 0.08% to 5,588,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/28/25 6:05:07 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and CFO Patel Snehal

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/17/25 6:05:39 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $89,358 worth of shares (10,600 units at $8.43), increasing direct ownership by 0.19% to 5,583,502 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/12/25 6:05:18 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $38,502 worth of shares (4,600 units at $8.37), increasing direct ownership by 0.08% to 5,588,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/28/25 6:05:07 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $89,358 worth of shares (10,600 units at $8.43), increasing direct ownership by 0.19% to 5,583,502 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/12/25 6:05:18 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $21,298 worth of shares (2,300 units at $9.26), increasing direct ownership by 0.04% to 5,572,902 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    11/4/25 6:16:15 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

    STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types (non-HLA-A*02) are planned to be treated with GLSI-100 in a third open label arm. The non-HLA-A*02 patients do not h

    12/8/25 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

    STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the equivalent of 600 patients per year in approximately 40 US sites and 100 EU sites for a total of 140 active sites. The Company is considering a

    12/3/25 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

    STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Austria. The Company's application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, Belgium, and the US. According to the latest data collected by the European Cancer Information System (click here), a t

    10/9/25 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLSI
    SEC Filings

    View All

    SEC Form 10-Q filed by Greenwich LifeSciences Inc.

    10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

    11/14/25 4:30:45 PM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Greenwich LifeSciences Inc.

    DEFA14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

    11/3/25 5:09:59 PM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Greenwich LifeSciences Inc.

    DEF 14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

    11/3/25 5:07:08 PM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Greenwich LifeSciences with a new price target

    Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00

    8/20/25 9:27:20 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Greenwich LifeSciences with a new price target

    HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00

    9/1/21 6:15:30 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital initiated coverage on Greenwich LifeSciences with a new price target

    Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

    1/27/21 6:00:07 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Greenwich LifeSciences Inc.

    SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)

    6/22/22 11:53:43 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care